Trial watch: Immune checkpoint blockers for cancer therapy
Year: 2017
Type: review
Abstract: Immune checkpoint blockers (ICBs) are literally revolutionizing the clinical management of an ever more diversified panel of oncological indications. Although considerable attention persists around the inhibition of cytotoxic T lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PDCD1, best known as PD-1) signaling, several other co-inhibitory T-cell receptors are being evaluated as potential targets for the development of novel ICBs. Moreover, substantial efforts are being devoted to the identification of biomarkers that reliably predict the likelihood of each patient to obtain clinical benefits from ICBs in the absence of severe toxicity. Tailoring the delivery of specific ICBs or combinations thereof to selected patient populations in the context of precision medicine programs constitutes indeed a major objective of the future of ICB-based immunotherapy. Here, we discuss recent preclinical and clinical advances on the development of ICBs for oncological indications.
Source: OncoImmunology
Institutions: Weill Cornell Medicine, Inserm, Institut Gustave Roussy, Centre de Recherche des Cordeliers, Université Paris Descartes, Université Pierre-et-Marie-Curie, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Charles University, University Hospital in Motol, Sotio (Czechia), Université Paris-Sud, Karolinska University Hospital, Karolinska Institutet
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,913
OpenAlex ID: W2750667003